The emergent healthcare value era, its consequences, and what drug firms need to do about it
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
IMS Health. IMS Health Reports Global Pharmaceutical Market Grew 7.0 Percent in 2006, to $643 Billion (IMS, Norwalk, CT, USA, March 20, 2007). http://www.imshealth.com/ims/portal/front/ articleC/0,2777,6599_3665_80560241,00.html
Author information
Authors and Affiliations
Ethics declarations
Competing interests
CardioVascular BioTherapeutics is a client of the Bruckner Group.
Rights and permissions
About this article
Cite this article
Russo, M., Balekdjian, D. Weighing the outcomes. Nat Biotechnol 26, 173–182 (2008). https://doi.org/10.1038/nbt0208-173
Issue Date:
DOI: https://doi.org/10.1038/nbt0208-173
This article is cited by
-
Is personalized medicine finally arriving?
Nature Biotechnology (2008)